AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Takeuchi Mfg., you have to believe the company can translate its expanded production base and solid revenue track record into sustainable, if measured, earnings growth, while continuing to reward shareholders through dividends and buybacks. The latest Q1 FY2027 update, with double-digit sales growth but weaker operating profit, puts a sharper spotlight on margins as the key short term catalyst: any sign of cost control or pricing power could quickly influence sentiment after the recent share price softness. At the same time, the decision to keep full-year guidance and lift the dividend to ¥220 per share suggests management is not treating this quarter as a structural setback, so the big picture on earnings trajectory and returns policy looks intact for now, but with less room for execution missteps.
However, margin pressure in the face of strong sales is a risk investors should not ignore. Despite retreating, Takeuchi Mfg's shares might still be trading 40% above their fair value. Discover the potential downside here.Explore 2 other fair value estimates on Takeuchi Mfg - why the stock might be worth as much as 67% more than the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com